News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Amgen Moves Three Cancer Drugs into Late-Stage Testing to Continue Growth
January 11, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Amgen Inc. may deepen a push into cancer drugs beyond denosumab, the medicine approved last year to delay bone fractures in cancer patients, with three new oncology products in late-stage testing.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Amgen
MORE ON THIS TOPIC
Immunology and inflammation
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
May 20, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
Relay doubles the bar, outpacing Novartis with a 60% response in rare disease
May 19, 2026
·
2 min read
·
Gabrielle Masson
Rare diseases
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop
May 19, 2026
·
2 min read
·
Tristan Manalac
Cancer
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer
May 19, 2026
·
2 min read
·
Tristan Manalac
